Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.K. warns against using arstolochia

This article was originally published in The Tan Sheet

Executive Summary

U.K. consumers should not use Xie Gan Wan pills, a Chinese product containing aristolochia, an unlicensed medicine the country banned in 1999, according to a Medicines and Healthcare products Regulatory Agency alert. MHRA identified a number of other products in recent years containing aristolochia, which can cause kidney failure. In 2004, California added aristolochic acid and other herbal remedies containing plant species of the genus aristolochia to the list of chemicals known to cause cancer (1"The Tan Sheet" July 12, 2004, In Brief)

You may also be interested in...



Aristolochic acid & Prop65

Aristolochic acid and "herbal remedies containing plant species of the genus Aristolochia" are added to California's list of chemicals known to cause cancer, the California Environmental Protection Agency's Office of Environmental Health Hazard Assessment announces. Effective July 9, the decision requires companies knowingly marketing products that contain the substance to include warning labels on product packaging. OEHHA says it received four public comments supporting the listing of these chemicals on the Prop 65 list of carcinogens. The proposal to include aristolochic acid on the list was announced in May (1"The Tan Sheet" May 31, 2004, p. 13)...

Did Sarepta Need To Tell Investors About Its Vyondys 53 Dispute Resolution Request?

Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.

Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning

Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.

Topics

UsernamePublicRestriction

Register

PS103978

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel